Braxia Scientific Corp. (BRAXF)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.31 Million CAD | 84.61% |
| 2022 | -8.51 Million CAD | 22.9% |
| 2021 | -11.04 Million CAD | -1270.49% |
| 2020 | -805.7 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -770.4 Thousand CAD | 41.21% |
| 2024 Q3 | 400.18 Thousand CAD | 411.15% |
| 2024 Q2 | -163.36 Thousand CAD | 78.8% |
| 2023 Q4 | -1.31 Million CAD | 1.87% |
| 2023 FY | -1.31 Million CAD | 84.61% |
| 2023 Q3 | -1.33 Million CAD | 70.18% |
| 2023 Q2 | -4.47 Million CAD | 40.42% |
| 2023 Q1 | -7.51 Million CAD | 11.72% |
| 2022 Q4 | -8.51 Million CAD | -12.97% |
| 2022 FY | -8.51 Million CAD | 22.9% |
| 2022 Q3 | -7.53 Million CAD | 20.79% |
| 2022 Q2 | -9.51 Million CAD | 6.3% |
| 2022 Q1 | -10.15 Million CAD | 8.05% |
| 2021 Q1 | -14.1 Million CAD | -835.12% |
| 2021 Q3 | -11.69 Million CAD | 6.8% |
| 2021 Q2 | -12.54 Million CAD | 11.07% |
| 2021 FY | -11.04 Million CAD | -1270.49% |
| 2021 Q4 | -11.04 Million CAD | 5.57% |
| 2020 Q4 | -1.5 Million CAD | -113.87% |
| 2020 Q3 | -705.38 Thousand CAD | 0.0% |
| 2020 FY | -805.7 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 213.417% |
| CSL Limited | 10.52 Billion USD | 100.012% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 108.313% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 131.822% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 426.107% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 103.062% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 79.214% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 241.337% |
| Mesoblast Limited | 55.85 Million USD | 102.346% |
| Marizyme, Inc. | 18.56 Million USD | 107.057% |
| Genus plc | 190.6 Million USD | 100.688% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 158.612% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 207.955% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 292.714% |
| ContraFect Corporation | -6.02 Million USD | 78.253% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1073.311% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 117.084% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 123.818% |
| MultiCell Technologies, Inc. | 90.04 USD | 1455515.371% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -78.542% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 110.122% |
| EV Biologics, Inc. | 1.36 Million USD | 195.796% |
| Q BioMed Inc. | 4.06 Million USD | 132.277% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 104.289% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 230.042% |
| Biomind Labs Inc. | 711.4 Thousand USD | 284.208% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 110.233% |
| Skye Bioscience, Inc. | -5.72 Million USD | 77.095% |
| SQZ Biotechnologies Company | -36.23 Million USD | 96.384% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1037.352% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 123.201% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 158.444% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 6696.144% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 310.561% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 101.193% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 252.336% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 159.513% |
| GB Sciences, Inc. | 1.74 Million USD | 174.998% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -613.026% |
| argenx SE | -2.02 Billion USD | 99.935% |
| HST Global, Inc. | 96.79 Thousand USD | 1453.875% |
| Halberd Corporation | 144.72 Thousand USD | 1005.505% |
| Enzolytics Inc. | 981.65 Thousand USD | 233.494% |
| Resverlogix Corp. | 6.45 Million USD | 120.314% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -94.693% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 103.017% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 102.164% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 97.213% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 165.543% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 118.533% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 464.309% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 148.381% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 85.176% |
| AVAX Technologies, Inc. | -5.9 Million USD | 77.801% |
| ONE Bio Corp. | 9.04 Million USD | 114.496% |
| Zenith Capital Corp. | 10.06 Thousand USD | 13121.224% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.877% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 753.816% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 154.922% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 896.586% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -7053.925% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 735.474% |
| Agentix Corp. | 37.63 Thousand USD | 3582.384% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -417.758% |
| Helix BioMedix, Inc. | -2.57 Million USD | 49.01% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 106.463% |
| BioStem Technologies, Inc. | 4.47 Million USD | 129.304% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 751.145% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -99934.809% |
| LadRx Corporation | -2.03 Million USD | 35.651% |
| Cell Source, Inc. | 9.23 Million USD | 114.195% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -6321.286% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 306.317% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 306.317% |
| NovAccess Global Inc. | 2.17 Million USD | 160.155% |
| Affymax, Inc. | -5.59 Million USD | 76.586% |
| Itoco Inc. | 228.3 Thousand USD | 673.994% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1063.649% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 126.436% |
| CytoDyn Inc. | 20.26 Million USD | 106.468% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -202443.431% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -14039.058% |
| Qrons Inc. | 351.42 Thousand USD | 472.896% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 117.006% |
| SYBLEU INC | 473.71 Thousand USD | 376.634% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -424.98% |
| Rebus Holdings, Inc. | 305 Thousand USD | 529.658% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 129.402% |
| Mobile Lads Corp. | 484.23 Thousand USD | 370.626% |
| International Stem Cell Corporation | 2.59 Million USD | 150.597% |
| Bioxytran, Inc. | 1.89 Million USD | 169.011% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 2199.652% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 160.088% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 138.161% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 115.322% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 269.615% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -4.836% |
| Neutra Corp. | 52.18 Thousand USD | 2611.077% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 47.35% |
| PureTech Health plc | -167.19 Million USD | 99.216% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -435.081% |
| IXICO plc | -4.44 Million USD | 70.516% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 109.913% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 102.389% |
| CSL Limited | 10.52 Billion USD | 100.012% |
| Cellectis S.A. | -43.81 Million USD | 97.009% |